Former Boston Scientific CEO James Tobin, who presided over the med-tech giant's
disastrous blockbuster acquisition of Guidant Corp., joins the board of directors at heart device maker Aptus Endosystems.
Former Boston Scientific Corp. (NYSE:BSX) CEO James Tobin joined the board of directors at Aptus Endosystems Inc., a device company specializing in treating abdominal aortic aneurysms.
Tobin made quite a name for himself while occupying the corner office at med-tech giant Boston Scientific, where he was chief for a decade. He officially retired in July 2009 and was succeeded by Ray Elliott.
Boston Scientific went through unprecedented growth during Tobin's tenure, with annual sales jumping from $2.8 billion to $8 billion in 2008, peaking at $8.4 billion in 2007. Tobin also led a hiring spree, more than doubling the size of the company – from 12,615 employees when he took the helm to a high-water mark of 28,600 in 2006.
But cost constraints and mounting debt prompted layoffs for about 4,000 workers over his last two years; at the end of 2008, the company employed 24,800 people worldwide.
In April 2009, Forbes named Tobin one of the "most overpaid" CEOs in business. He took home $8.6 million in total compensation in 2008, slightly less than the $9 million he received in 2007. He walked away from the device giant with a severance deal worth $5 million.
The most recent Boston Scientific mesh lawsuit, which cost the company $74 million, featured an...
Intersect ENT enrolls the 1st patient in its PROGRESS study, aiming to expand the patient population...
Innovative needle design to enhance patient safety.
Medtronic taps Dr. Elizabeth Nabel, president of Brigham & Women's Faulkner Hospital in Boston,...